If you are not happy with the results below please do another search
The drug hydroxychloroquine, once touted by Donald Trump as a pandemic “game-changer,” should not be used to prevent Covid-19 and has no meaningful effect on patients already infected, a World Health Organization expert panel said.
U.S. vaccine developer Inovio Pharmaceuticals completed Phase II enrollment for a mid-to-late stage U.S. trial of the company’s Covid-19 vaccine candidate and expects to report data early in the second quarter.
The United States reported a 3% decline in new cases of Covid-19 for the week ended Feb. 28, a much smaller drop than in the previous six weeks, and health officials warned that progress against the global pandemic was stalling.
The number of new coronavirus infections globally rose for the first time in seven weeks, the World Health Organization said on March 1.
Reuters reported that AstraZeneca sold off the U.K. pharma giant’s 7.7 percent stake in the Covid-19 vaccine manufacturer Moderna for more than $1 billion.
The U.S. Food and Drug Administration approved BridgeBio Pharma and affiliate Origin Biosciences’ injectable, rare genetic metabolic disorder therapy Nulibry (fosdenopterin).
Darmstadt, Germany-based Merck KGaA plunked down €188 million (about $226 million) in upfront cash to acquire exclusive global development and commercialization rights to Debiopharm’s oral Inhibitor of Apoptosis Proteins (IAP) antagonist, xevinapant.
Nearly two thirds of Russians are not willing to receive Russia’s Sputnik V vaccine, and about the same number believe the new coronavirus was created artificially as a biological weapon, an independent pollster said on March 1.
Johnson & Johnson’s newly authorized Covid-19 vaccine started shipping and the company’s top executive said on March 1 that Americans should be able to receive the single-dose shot within 24 to 48 hours, adding a third vaccine in the United States.
The U.S. Food and Drug Administration approved Oncopeptides AB’s Pepaxto (melphalan flufenamide) in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD38-directed monoclonal antibody.